Colospan
- Company typePrivate
- Founded2009
- HeadquartersKfar Saba, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Colospan firmographics
Firmographics- Name
- Colospan
- Legal name
- Colospan Ltd.
- Website
- https://colospan.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Colospan industry classification
Industry- Product category
- Colorectal Surgery Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)
Keywords
Where Colospan is headquartered
LocationHeadquarters
- HQ city
- Kfar Saba
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
Colospan business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Colospan generates revenue through the sale of its CG-100 intraluminal bypass device. The device is currently commercially available in the European Union and Israel, with plans to expand commercialization to Germany, Austria, and Switzerland in H2 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Device pricing for hospitals and surgical centers |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Colospan product offering
Product offeringCore offering
Colospan develops, manufactures, and commercializes the CG-100 intraluminal bypass device, a CE-marked soft silicone device placed through the anus during colorectal surgery to protect the anastomosis site. The device uses inflatable balloons and a securing ring for in-place retention and is removed non-surgically after 10 days as an alternative to diverting stoma. It is sold to hospitals and surgical centers across the EU and Israel, with U.S. availability through an active FDA IDE pivotal trial.
Product overview
Colospan is a commercial-stage medical device company with a single flagship product: the CG-100 intraluminal bypass device. The CG-100 is a CE-marked (under EU MDR) and Israel-approved device designed as an alternative to diverting stomas in colorectal surgery. It is made of soft silicone, deployed during primary surgery through the anus, uses inflatable balloons and a securing ring to protect the surgical anastomosis site, and is removed non-surgically after 10 days. The company is currently conducting a pivotal clinical study under FDA Investigational Device Exemption (IDE) with FDA Breakthrough Device Designation for the U.S. market.
Differentiator
Problem solved
Functional benefit
Products and services
- CG-100 Intraluminal Bypass Device The CG-100 is a CE-marked (under EU MDR) intraluminal bypass device made of soft silicone that is placed through the anus during colorectal surgery to protect the surgical anastomosis. It uses inflatable balloons and a securing ring to stay in place and is removed non-surgically after 10 days as an alternative to diverting stoma, intended for hospitals and surgical centers performing colorectal cancer resections.
Quantifiable outcome
- Up to 20% of colorectal surgery patients experience anastomotic leaks; CG-100 clinical data shows 3% leak rate
- +3 more outcomes
Companies that use Colospan
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Colospan technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Colospan partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Galmed PharmaceuticalscoreGalmed Pharmaceuticals acquired Colospan Ltd. in a $4.5 million deal ($2.5 million cash plus $2.0 million in Galmed ordinary shares, with restructured terms adding $800,000 cash and replacing $2.0 million share payment with earnout capped at $2.0 million from Q3 2027). The acquisition creates a GI-focused medtech platform targeting the $6 billion gastrointestinal market addressing anastomotic leak complications in colorectal surgery.
- Asklepios Altona CliniccoreAsklepios Altona Clinic in Hamburg became the first hospital in Germany to use the novel CG-100 intraluminal device in patients undergoing colorectal surgery, marking a key European clinical adoption partnership.
- Clalit HMOmajorClalit HMO, a major Israeli health maintenance organization, executed a purchasing code for the CG-100 intraluminal bypass device, representing a significant commercial distribution partnership in the Israeli market.
- Henry Ford HospitalcoreHenry Ford Hospital in Detroit was the first in the United States to perform an investigational procedure with the CG-100 intraluminal device in patients undergoing colorectal anastomosis as part of the FDA IDE clinical trial.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Colospan competitors and assessment
Company assessmentBroad incumbents
- Ethicon (Johnson & Johnson): Ethicon is the largest manufacturer of surgical staplers and anastomosis products used in colorectal surgery. Its portfolio competes for share of the same procedure budget that CG-100 targets, and any new anastomotic protection device must be benchmarked against Ethicon's installed stapling systems.
- Medtronic: Medtronic (via the former Covidien) is a major supplier of surgical staplers, GI stents, and colorectal surgery devices. Its broad GI and surgical portfolios overlap with the clinical workflow in which CG-100 is deployed.
- Boston Scientific: Boston Scientific has a substantial GI and endoscopy portfolio including intraluminal devices and stents. It serves the same gastroenterology and colorectal surgery customers and competes for procedural budgets.
- Olympus Corporation: Olympus is a leading manufacturer of GI endoscopes and related therapeutic accessories. Its installed base defines the GI procedural environment in which CG-100 must integrate and gain surgeon acceptance.
- Becton Dickinson (BD): BD manufactures surgical instruments and a growing portfolio of GI and colorectal intervention products. Its scale and hospital relationships make it a relevant incumbent peer for any surgical GI device commercialization.
- B. Braun Melsungen: B. Braun supplies surgical instruments, GI devices, and colorectal surgery products globally. Its broad surgical portfolio and European footprint make it a relevant comparable for CG-100's planned EU commercialization.
Direct peers
- Cook Medical: Cook Medical manufactures GI and colorectal devices including stents and intraluminal products. Its focus on GI intervention makes it the most directly comparable medtech peer in terms of clinical call point and product type.
- Applied Medical Resources: Applied Medical produces surgical access and colorectal surgery devices used in the same operating room procedures as CG-100. Its portfolio includes access systems and wound protection products that intersect with the colorectal surgery workflow.
Emerging players
- Intuitive Surgical: Intuitive Surgical's da Vinci platform is widely used for robotic colorectal resection, the procedure in which CG-100 is deployed. While not a direct device competitor, it shapes the surgical workflow and adoption dynamics for adjunct devices like CG-100.
- Conmed Corporation: Conmed is a smaller medtech company focused on surgical and GI devices. Its narrower portfolio and overlap with colorectal procedural products make it a useful emerging-player comparable for Colospan's scale and stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Colospan social profiles
Digital presenceColospan compliance and trust
Trust signalCompliance3 records
Colospan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Colospan leadership team
Management profileNumber of profiles
Profiles6 records
Colospan funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Colospan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Colospan
What does Colospan do?
Colospan develops, manufactures, and commercializes the CG-100 intraluminal bypass device, a CE-marked soft silicone device placed through the anus during colorectal surgery to protect the anastomosis site. The device uses inflatable balloons and a securing ring for in-place retention and is removed non-surgically after 10 days as an alternative to diverting stoma. It is sold to hospitals and surgical centers across the EU and Israel, with U.S. availability through an active FDA IDE pivotal trial.
Is Colospan a public or private company?
Colospan is a private company. It is classified as corporate owned and is currently acquired.
When was Colospan founded?
Colospan was founded in 2009. It employs 11 to 50 people.
Where is Colospan based?
Colospan is headquartered in Kfar Saba, Israel, in the Middle East region.
How does Colospan make money?
One revenue line is on record: medical Device Sales.
Who are Colospan's main competitors?
Broad incumbents on record are Ethicon (Johnson & Johnson), Medtronic, Boston Scientific, Olympus Corporation, Becton Dickinson (BD) and B. Braun Melsungen. Direct peers are Cook Medical and Applied Medical Resources. Emerging players are Intuitive Surgical and Conmed Corporation.
Does Colospan have an API?
No public API is recorded for Colospan.
What industry is Colospan in?
Colospan's product category is Colorectal Surgery Medical Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation). Its NAICS code is 339112 and its SIC code is 3841.